Abbvie Inc

NYSE: ABBV
$189.45
-$0.23 (-0.1%)
Closing Price on October 29, 2024

ABBV Articles

AbbVie saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small cell lung cancer trial.
Jefferies has made a big move by adding a top retail company to its well-respected Franchise Picks list of stocks to Buy.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
These five stocks come with upward earnings revisions and the potential for rising dividends. They all make good sense for investors looking for stocks ideas as we get closer to the second quarter.
These were 13 stock buyback and dividend hike announcements from the week of February 16 that were simply too large to be ignored.
AbbVie is joining the companies raising their shareholder rewards. The pharmaceutical products maker has announced how it will further commit to previously forecast moves.
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
While not the most exciting companies in the world, these five Dividend Aristocrats will certainly hold up much better than others should the market take a deep dive.
The top analyst upgrades, downgrades and other research calls from Monday include AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp and Splunk.
Friday was a positive day for the U.S. markets. We are currently in the midst of the fourth quarter earnings season and so far it has been very positive for the markets, pushing all of the exchanges...
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
24/7 Wall St. has put together a preview of Netflix, Ford, AbbVie and other top companies reporting their latest quarterly results in the coming week.